+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy



Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy



Terapevticheskii Arkhiv 89(1): 82-87



Аннотация Число пациентов, получающих статины, увеличивается с каждым годом, и в связи с необходимостью их пожизненного приема проблема безопасности применения статинов выходит на первый план. В статье проанализирована проблема безопасности применения препаратов данной группы, обсуждаются вопросы диагностики миопатий, индуцированных статинами, а также проблема возникновения иммуноопосредованных статиновых миопатий. Рассмотрен персонализированный подход к назначению статинов, проанализирован отечественный и зарубежный опыт применения фармакогенетики с целью снижения риска развития миопатий, опубликованы результаты собственного опыта внедрения фармакогенетического тестирования в клиническую практику в условиях функционирования стационара, проведен анализ отдаленных результатов использования определения полиморфизма гена SLCO1B1 для прогнозирования риска развития нежелательных явлений при применении статинов, оценки степени соблюдения пациентами схем назначенного лечения.

(PDF emailed within 1 workday: $29.90)

Accession: 060449610

Download citation: RISBibTeXText

PMID: 28252633


Related references

A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions. Pharmacoeconomics 34(8): 771-793, 2017

Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?. Psychiatry Research 271: 604-613, 2018

Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transplantation 11(7): 826-833, 2005

Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects. International Journal of Technology Assessment in Health Care 24(3): 294-302, 2008

Prediction of severe adverse drug reactions using pharmacogenetic biomarkers. Drug Metabolism and Pharmacokinetics 25(2): 122-133, 2010

Pharmacogenetic markers of severe cutaneous adverse drug reactions. Giornale Italiano di Dermatologia E Venereologia 149(2): 219-226, 2014

Pharmacogenetic markers for antihypertensive drug-related adverse reactions. Pharmacogenomics 14(15): 1819-1820, 2014

Pharmacogenetic Biomarkers as Tools for Pharmacoepidemiology of Severe Adverse Drug Reactions. Drug Development Research 74(1): 1-14, 2013

Pharmacogenetic research in the association between human leukocyte antigen and adverse drug reactions. Zhong Nan Da Xue Xue Bao. Yi Xue Ban 39(7): 749-757, 2015

Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response. Drug Metabolism and Drug Interactions 29(2): 67-79, 2014

Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening. Cmaj 182(5): 476-480, 2010

Pilot testing of checklists to discern adverse drug reactions and adverse drug events. Journal of the American Pharmacists Association 53(1): 61-69, 2013

Statin drug interactions and related adverse reactions. Expert Opinion on Drug Safety 11(6): 933-946, 2013

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies. Oncotarget 7(49): 81870-81879, 2016

Pharmacogenetic effect on the therapeutic safety of metoprolol Association of CYP2D6 genotype and adverse drug reactions. Circulation 104(17 Supplement): II 285, October 23, 2001